is ART 123 results a blow for GTCB's DIC studies or not?
Humour me, I cant quite figure it out ART 123 is from Artisan as far as I know, could anyone be so kind to inform me how we have to see GTCB DIC studies in this retrospect?
My error. Could in theory a phase IIb study (if extremly positive) serve as a basis for approval or is a phase III study always necessary. If for example a survival benefit were shown in spite of the original design that was not powered to do so. Thanks, bp